

NCT01742117 comparison:

Summary:
CHIA has 30 criteria while your personal folder has 30 criteria
Total found criteria: 29/30
Total not Found: 1/30
Total Extra: 3
This trial is INVALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Patient >18 years of age                           │ Patient \>18 years of age                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patient presents with acute coronary syndrome      │ Patient presents with acute coronary syndrome      │
│ (ACS) or stable coronary artery disease (CAD)      │ (ACS) or stable coronary artery disease (CAD)      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patient is eligible for PCI                        │ Patient is eligible for PCI                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patient is willing and able to provide informed    │ Patient is willing and able to provide informed    │
│ written consent                                    │ written consent                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patient not able to receive 12 months of dual      │ Patient not able to receive 12 months of dual      │
│ anti-platelet therapy                              │ anti-platelet therapy                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Failure of index PCI                               │ Failure of index PCI                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patient or physician refusal to enroll in the      │ Patient or physician refusal to enroll in the      │
│ study                                              │ study                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patient with known CYP2C19 genotype prior to       │ Patient with known CYP2C19 genotype prior to       │
│ randomization                                      │ randomization                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Planned revascularization of any vessel within 30  │ Planned revascularization of any vessel within 30  │
│ days post-index procedure and/or of the target     │ days post-index procedure and/or of the target     │
│ vessel(s) within 12 months post-procedure          │ vessel(s) within 12 months post-procedure          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Anticipated discontinuation of clopidogrel or      │ Anticipated discontinuation of clopidogrel or      │
│ ticagrelor within the 12 month follow up period,   │ ticagrelor within the 12 month follow up period,   │
│ example for elective surgery                       │ example for elective surgery                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Serum creatinine >2.5 mg/dL within 7 days of index │ Serum creatinine \>2.5 mg/dL within 7 days of      │
│ procedure                                          │ index procedure                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Platelet count <80,000 or >700,000 cells/mm3, or   │ Platelet count \<80,000 or \>700,000 cells/mm3, or │
│ white blood cell count <3,000 cells/mm3 if         │ white blood cell count \<3,000 cells/mm3 if        │
│ persistent (at least 2 abnormal values) within 7   │ persistent (at least 2 abnormal values) within 7   │
│ days prior to index procedure                      │ days prior to index procedure                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of intracranial hemorrhage                 │ History of intracranial hemorrhage                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Known hypersensitivity to clopidogrel or           │ Known hypersensitivity to clopidogrel or           │
│ ticagrelor or any of its components                │ ticagrelor or any of its components                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patient is participating in an investigational     │ Patient is participating in an investigational     │
│ drug or device clinical trial that has not reached │ drug or device clinical trial that has not reached │
│ its primary endpoint                               │ its primary endpoint                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patient previously enrolled in this study          │ Patient previously enrolled in this study          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patient is pregnant, lactating, or planning to     │ Patient is pregnant, lactating, or planning to     │
│ become pregnant within 12 months                   │ become pregnant within 12 months                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patient has received an organ transplant or is on  │ Patient has received an organ transplant or is on  │
│ a waiting list for an organ transplant             │ a waiting list for an organ transplant             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patient is receiving or scheduled to receive       │ Patient is receiving or scheduled to receive       │
│ chemotherapy within 30 days before or after the    │ chemotherapy within 30 days before or after the    │
│ procedure                                          │ procedure                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patient is receiving immunosuppressive therapy or  │ Patient is receiving immunosuppressive therapy or  │
│ has known immunosuppressive or autoimmune disease  │ has known immunosuppressive or autoimmune disease  │
│ (e.g., human immunodeficiency virus, systemic      │ (e.g., human immunodeficiency virus, systemic      │
│ lupus erythematous, etc.)                          │ lupus erythematous, etc.)                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patient is receiving chronic oral anticoagulation  │ Patient is receiving chronic oral anticoagulation  │
│ therapy (i.e., vitamin K antagonist, direct        │ therapy (i.e., vitamin K antagonist, direct        │
│ thrombin inhibitor, Factor Xa inhibitor)           │ thrombin inhibitor, Factor Xa inhibitor)           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Concomitant use of simvastatin/lovastatin > 40 mg  │ Concomitant use of simvastatin/lovastatin \> 40 mg │
│ qd                                                 │ qd                                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Concomitant use of potent CYP3A4 inhibitors        │ Concomitant use of potent CYP3A4 inhibitors        │
│ (atazanavir, clarithromycin, indinavir,            │ (atazanavir, clarithromycin, indinavir,            │
│ itraconazole, ketoconazole, nefazodone,            │ itraconazole, ketoconazole, nefazodone,            │
│ nelfinavir, ritonavir, saquinavir, telithromycin   │ nelfinavir, ritonavir, saquinavir, telithromycin   │
│ and voriconazole) or inducers (carbamazepine,      │ and voriconazole) or inducers (carbamazepine,      │
│ dexamethasone, phenobarbital, phenytoin, rifampin, │ dexamethasone, phenobarbital, phenytoin, rifampin, │
│ and rifapentine)                                   │ and rifapentine)                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Non-cardiac condition limiting life expectancy to  │ Non-cardiac condition limiting life expectancy to  │
│ less than one year, per physician judgment (e.g.   │ less than one year, per physician judgment (e.g.   │
│ cancer)                                            │ cancer)                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Known history of severe hepatic impairment         │ Known history of severe hepatic impairment         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patient has a history of bleeding diathesis or     │ Patient has a history of bleeding diathesis or     │
│ coagulopathy or will refuse blood transfusions     │ coagulopathy or will refuse blood transfusions     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patient has an active pathological bleeding, such  │ Patient has an active pathological bleeding, such  │
│ as active gastrointestinal (GI) bleeding           │ as active gastrointestinal (GI) bleeding           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Inability to take aspirin at a dosage of 100 mg or │ Inability to take aspirin at a dosage of 100 mg or │
│ less                                               │ less                                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Current substance abuse (e.g., alcohol, cocaine,   │ Current substance abuse (e.g., alcohol, cocaine,   │
│ heroin, etc.)                                      │ heroin, etc.)                                      │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



╒═══════════════════════════════════════╕
│ CHIA Criteria Not Found in Personal   │
╞═══════════════════════════════════════╡
│ NA                                    │
╘═══════════════════════════════════════╛



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ 3 Exclusion                       │
├───────────────────────────────────┤
│ Must have minimum age of 18 Years │
├───────────────────────────────────┤
│ Inclusion                         │
╘═══════════════════════════════════╛